Using its advanced capabilities in the generation and interpretation of sequencing data to analyse whole genomes, exomes and transcriptomes, Personalis built a significant business analyzing patient samples for pharmaceutical and biotech companies and sequencing whole genomes for the US Department of Veteran Affairs (VA)’s Million Veterans Program. The company enjoyed a successful IPO in 2019 and subsequently expanded its offerings to include advanced genomic tests that detect ultra-low traces of minimal residual disease (MRD) and recurrence, uncover deeper insights for therapy selection, and power the design of individualized neoantigen therapies. In July 2026, Personalis announced that it is to be acquired by Tempus.